EHA 2023 | The role of daratumumab and dara-CyBorD in newly diagnosed and advanced stage AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses recent advances in the treatment of light chain (AL) amyloidosis, commenting on the role of daratumumab and daratumumab, cyclophosphamide, bortezomib, and dexamethasone (daraCyBorD) in patients with newly diagnosed and advanced stage disease. While daraCyBorD has been approved in newly diagnosed patients, the use of daratumumab and daraCyBorD is unclear in patients with stage IIIb AL amyloidosis and remains a population of unmet need. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
